Replies to post #144065 on Biotech Values

[jq1234]

That's Carfilzomib's key weakness in its NDA application IMO. ONXX basically used dexamethasone during initial treatment cycles to mitigate risks, but didn't identify cardiac and hepatic risk patients for dose reduction as Velcade did.